Oral ZD1839 (IRESSA®) Versus Intravenous Docetaxel (TAXOTERE®) in Patients With Non-Small Cell Lung Cancer
|
Summary The purpose of this study is to compare the overall survival between ZD1839 (Iressa®) and docetaxel. Patients must be 18 years or over with locally advanced or metastatic recurrent non-small cell lung cancer that have previously received platinum-based chemotherapy. Platinum-based chemotherapy regimens will most commonly consist of either cisplatin or carboplatin in combination with one of the following chemotherapeutic agents: paclitaxel, gemcitabine, vinorelbine, or docetaxel. Patients will either be given ZD1839 250mg/day orally or docetaxel 75 mg intravenously over 1 hour every 3 weeks. Eligibility Criteria Inclusion Criteria:
Exclusion Criteria:
Disclaimer Information about this trial is from the ClinicalTrials.gov database. The versions designated for health professionals and patients contain the same text. Minor changes may be made to the ClinicalTrials.gov record to standardize the names of study sponsors, sites, and contacts. Cancer.gov only lists sites that are recruiting patients for active trials, whereas ClinicalTrials.gov lists all sites for all trials. Questions and comments regarding the presented information should be directed to ClinicalTrials.gov. Trial Contact Information Trial Lead Organizations/Sponsors AstraZeneca Pharmaceuticals LP Trial Sites and Contacts
*** POSTED JUNE 7, 2004 *** |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
